Status:
COMPLETED
Evaluating Serum Sestrin in Leiomyoma Patients
Lead Sponsor:
Sisli Hamidiye Etfal Training and Research Hospital
Conditions:
Uterine Leiomyoma
Eligibility:
FEMALE
18-45 years
Brief Summary
Leiomyomas are the most common benign neoplasms of women's reproductive system affecting 20-30% of women within the reproductive ages. Sestrins are serum proteins which are highly expressed under circ...
Detailed Description
Leiomyomas are the benign neoplasms of uterus and the role of genetics, estrogen levels and obesity has already been shown in their development. Higher levels of serum sestrin proteins have already be...
Eligibility Criteria
Inclusion
- 18-45 years of age
- patients diagnosed with uterine leiomyomas will be included in the study group
- patients without any additional comorbidities
- patients without any autoimmune diseases
Exclusion
- patients with systemic diseases
- patients with known chronic inflammatory diseases
- patients using hormonal and/or medical therapy
- pregnant women
- lactating women
- patients with malignant diseases
Key Trial Info
Start Date :
January 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 1 2021
Estimated Enrollment :
61 Patients enrolled
Trial Details
Trial ID
NCT04819633
Start Date
January 1 2021
End Date
April 1 2021
Last Update
September 21 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sisli Hamidiye Etfal Training and Research Hospital
Istanbul, Turkey (Türkiye), 34371